Generic Brenzavvy Availability
Last updated on Apr 10, 2025.
Brenzavvy is a brand name of bexagliflozin, approved by the FDA in the following formulation(s):
BRENZAVVY (bexagliflozin - tablet;oral)
-
Manufacturer: THERACOSBIO
Approval date: January 20, 2023
Strength(s): 20MG [RLD]
Is there a generic version of Brenzavvy available?
An Authorized Generic version of Brenzavvy has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.
List of authorized generic versions:
- Bexagliflozin ORAL TABLET 20 mg
Golden State Medical Supply, Inc.
NDC Code: 514070918 - Bexagliflozin ORAL TABLET 20 mg
TheracosBio, LLC
NDC Code: 823812000
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Brenzavvy. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Crystalline form of benzylbenzene SGLT2 inhibitor
Patent 10,533,032
Issued: January 14, 2020
Inventor(s): Cai Mengzhuang & Liu Qian & Xu Ge & Lv Binhua & Seed Brian & Roberge Jacques
Assignee(s): THERACOS SUB, LLCProvided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
Patent expiration dates:
- July 3, 2031✓
- July 3, 2031
-
Crystalline form of benzylbenzene SGLT2 inhibitor
Patent 10,981,942
Issued: April 20, 2021
Inventor(s): Cai; Mengzhuang et al.
Assignee(s): THERACOS SUB, LLC (Marlborough, MA)Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
Patent expiration dates:
- June 13, 2031✓✓
- June 13, 2031
-
Benzylbenzene derivatives and methods of use
Patent 7,838,499
Issued: November 23, 2010
Inventor(s): Chen; Yuanwei et al.
Assignee(s): Theracos, Inc. (Sunnyvale, CA)Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
Patent expiration dates:
- January 30, 2029✓✓✓
- January 30, 2029
-
Benzylbenzene derivatives and methods of use
Patent 8,106,021
Issued: January 31, 2012
Inventor(s): Chen Yuanwei & Cheng Huawei & Li Shengbin & Wu Yuelin & Feng Yan & Lv Binhua & Xu Baihua & Seed Brian & Hadd Michael J. & Song Yanli & Du Jiyan & Wang Congna & Roberge Jacques Y.
Assignee(s): Theracos, Inc.Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
Patent expiration dates:
- August 22, 2028✓
- August 22, 2028
-
Benzylbenzene derivatives and methods of use
Patent 8,802,637
Issued: August 12, 2014
Inventor(s): Chen Yuanwei & Cheng Huawei & Li Shengbin & Wu Yuelin & Feng Yan & Lv Binhua & Xu Binhua & Seed Brian & Hadd Michael J. & Song Yanli & Du Jiyan & Wang Congna & Roberge Jacques Y.
Assignee(s): Theracos, Inc.Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
Patent expiration dates:
- August 22, 2028✓✓✓
- August 22, 2028
-
Crystalline form of benzylbenzene SGLT2 inhibitor
Patent 8,987,323
Issued: March 24, 2015
Inventor(s): Cai Mengzhuang & Liu Qian & Xu Ge & Lv Binhua & Seed Brian & Roberge Jacques Y.
Assignee(s): Theracos, Inc.Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
Patent expiration dates:
- May 14, 2032✓✓
- May 14, 2032
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- January 20, 2028 - NEW CHEMICAL ENTITY
More about Brenzavvy (bexagliflozin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: SGLT-2 inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
